Dr. Albert Deisseroth, president and CEO for the Sidney Kimmel Cancer Center, San Diego:
"Clinical testing will begin next spring on a vaccine for treating
breast cancer. The vaccine, which has been in development for more than five years, works by activating the body's immune system to suppress the recurrence of
breast cancer following initial surgery. The process initiates an immune response against a self-antigen known as MUC-1. The antigen exhibits altered structure and expression in
breast cancer. Injection of this vaccine under the skin can provide up to one year's resistance against the growth of cancer cells. The vaccine may be effective against other forms of cancer as well."
The clinical testing will begin in a few months in part to a $250,000 grant from the Breast Cancer Research Foundation.
ProfNet
Ste 200, 888 Veterans Highway
Hauppauge, NY 11788
United States
profnet.com
Threaded Mode